Cargando…
Maxing Shigan Decoction Mitigates Mycoplasma pneumonia-Induced Pyroptosis in A549 Cells via the NLRP3 Inflammasome
BACKGROUND: Mycoplasma pneumoniae is a predominant cause of community-acquired respiratory infections. We recently discovered the clinical efficacy of Maxing shigan decoction (MXSG) in M. pneumoniae infection and designed a study to explore the mechanism of action. METHODS: Serum IL-1β, IL-18, and T...
Autores principales: | Liu, Fang, Liu, TianTian, Sun, Min, Zhou, JingMin, Xue, Feng, Chen, ShuangHui, Chen, Jia, Zhang, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937399/ https://www.ncbi.nlm.nih.gov/pubmed/33688221 http://dx.doi.org/10.2147/IDR.S292413 |
Ejemplares similares
-
Efficacy and safety of Maxing Shigan Decoction in the treatment of chronic obstructive pulmonary disease: A protocol for a systematic review and meta-analysis
por: Chen, Jinyun, et al.
Publicado: (2020) -
Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification
por: Li, Yuan, et al.
Publicado: (2021) -
Application of Jiawei Maxing Shigan Tang in the treatment of COVID-19: An observational study
por: Wu, Jia, et al.
Publicado: (2022) -
Pyroptosis in NLRP3 inflammasome-related atherosclerosis
por: Zeng, Xiang, et al.
Publicado: (2022) -
PPM1A as a key target of the application of Jiawei-Maxing-Shigan decoction for the attenuation of radiation-induced epithelial-mesenchymal transition in type II alveolar epithelial cells
por: Lu, Jinhua, et al.
Publicado: (2021)